Correction to Company Announcement No. 13 of March 2, 2026 Company Announcement COPENHAGEN, Denmark; March 2, 2026 – (Nasdaq: GMAB) - Correction: In Company Announcement no. 13/2026 regarding transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons it was reported that the share price associated with these transactions was DKK 0,00. The correct price is DKK 1,867.50. In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the tr...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons Company Announcement COPENHAGEN, Denmark; March 2, 2026 – (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The Company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to p...
Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; March 2, 2026 – Genmab A/S (Nasdaq: GMAB). On February 17, 2026, Genmab announced the initiation of a share buy-back program to repurchase up to 342,130 shares with a maximum aggregate total value of DKK 725 million to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected to be completed no later than March 31, 2026. The following transactions were executed under the program from February 23 to February 27, 2026: No. of sharesAverage price (DKK...
Borregaard ASA: Shares for employees 2026 2 March 2026: Borregaard ASA (“Borregaard”, OSE ticker: BRG) Reference is made to the stock exchange notices of 9 and 16 February regarding the shares to employees’ programme. Today Borregaard transferred in total 212,596 shares to the 503 employees who participated in this year’s programme. After this transfer Borregaard owns 55,867 treasury shares. Contact:Lotte Kvinlaug, Investor Relations Officer,
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons Company Announcement COPENHAGEN, Denmark; February 27, 2026 – (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf ...
Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab Company Announcement COPENHAGEN, Denmark; February 27, 2026 – (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 587,495 restricted stock units to members of management and employees of the Company as well as the Company's subsidiaries and 455,004 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK...
Genmab to Participate in Upcoming Investor Conferences Media ReleaseCOPENHAGEN, Denmark; February 25, 2026 (Nasdaq: GMAB) announced today that members of its Executive Committee will participate in fireside chats at the following investor conferences in March 2026: TD Cowen 46th Annual Healthcare Conference in Boston on March 3, 2026, 9:10 AM EST (3:10 PM CET)Leerink Global Healthcare Conference in Miami on March 10, 2026, 8:40 AM EDT (1:40 PM CET)Barclays 28th Annual Global Healthcare Conference in Miami on March 11, 2026, 1:30 PM EDT (6:30 PM CET) The live and archived webcast of the p...
Capital Increase in Genmab as a Result of Employee Warrant Exercise Company Announcement COPENHAGEN, Denmark; February 24, 2026 – (Nasdaq: GMAB) will increase its share capital by 12,313 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 710 shares at DKK 1,147.50,239 shares at DKK 1,155.00,1,527 shares at DKK 1,161.00,1,183 shares at DKK 1,334.50,5,391 shares at DKK 1,362.50, and3...
Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; February 23, 2026 – Genmab A/S (Nasdaq: GMAB). On February 17, 2026, Genmab announced the initiation of a share buy-back program to repurchase up to 342,130 shares with a maximum aggregate total value of DKK 725 million to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected to be completed no later than March 31, 2026. The following transactions were executed under the program from February 18 to February 20, 2026: No. of sharesAverage price ...
Borregaard ASA: Reporting of transactions in Borregaard ASA's shares made by person discharging managerial responsibilities 23.02.26: Borregaard ASA ("Borregaard", OSE ticker: BRG) Borregaard's Board of Directors has issued share options in accordance with the proxy given by the Annual General Meeting held on 10 April 2025. The total number of options issued is 393,000. The options will expire after five years (23 February 2031) and may be exercised in the last two years. The strike price of the options is NOK 193.27. It is based on the volume weighted average share price (VWAP) during th...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons Company Announcement COPENHAGEN, Denmark; February 20, 2026 – (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf ...
A director at Telenor ASA maiden bought 3,436 shares at 173.800NOK and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...
Notice to Convene the Annual General Meeting of Genmab A/S Company Announcement Genmab A/S to hold Annual General Meeting on Thursday March 19, 2026 COPENHAGEN, Denmark; February 18, 2026 – (Nasdaq: GMAB) summons the Annual General Meeting on Thursday, March 19, 2026, at 2:00 PM CET at the Copenhagen Marriott Hotel, Kalvebod Brygge 5, DK-1560 Copenhagen V, Denmark. The notice for the Annual General Meeting, including Appendix 1: Candidates for the Board of Directors, is attached. About Genmab Genmab is an international biotechnology company dedicated to improving the lives of people ...
Genmab Announces Initiation of Share Buy-Back Program Company Announcement Repurchase of up to 342,130 shares with a maximum aggregate total value of 725 million DKK Honoring our commitments under the Restricted Stock Unit programCompletion expected no later than March 31, 2026 COPENHAGEN, Denmark; February 17, 2026 – (Nasdaq: GMAB) announced today that it is initiating a share buy-back program, to honor our commitments under the Restricted Stock Unit program. The share buy-back program will be undertaken on the terms set out below and in accordance with Regulation (EU) No. 596/2014 (‘M...
Genmab Files Annual Report with the U.S. Securities and Exchange Commission Media ReleaseCOPENHAGEN, Denmark; February 17, 2026 Genmab filed Form 20-F for the financial year 2025 with the U.S. SEC (Nasdaq: GMAB) announced today that it has filed its Annual Report for the financial year 2025 on Form 20-F with the U.S. Securities and Exchange Commission (SEC), incorporating by reference parts of the Genmab A/S Annual Report 2025. Both reports are available via the SEC’s website, and Genmab’s website, . About Genmab Genmab is an international biotechnology company dedicated to improving t...
Genmab Publishes 2025 Annual Report Company Announcement COPENHAGEN, Denmark; February 17, 2026 – (Nasdaq: GMAB) announced today the publication of its Annual Report for 2025. Below is a summary of business progress in 2025, financial performance for the year and the financial outlook for 2026. The full report is attached as a PDF file and in iXBRL format and can be found in the investor section of the company’s website, . Conference CallGenmab will hold a conference call to discuss the full year results for 2025 today, February 17, 2026 at 6:00 pm CET, 5:00 pm GMT, 12:00 pm EST. To join...
Borregaard ASA: Reporting of transactions in Borregaard ASA's share options by person discharging managerial responsibilities 16.02.2026: Borregaard ASA ("Borregaard", OSE ticker: BRG) The following persons discharging managerial responsibilities (primary insiders) have on 16.02.2026 exercised the number of share options as shown below at a strike price of NOK 164.45 per share and in separate transactions, purchased and sold the same number of shares. After the transactions the persons have the following holdings of options and shares in Borregaard (exercised share options in parenthesis):...
Borregaard ASA: Reporting of transactions in Borregaard ASA's shares made by person discharging managerial responsibilities 16 February 2026 Borregaard ASA (“Borregaard”, OSE ticker: BRG) Reference is made to the stock exchange notice of 9 February 2026 regarding the shares to employees’ programme. The share price was fixed at NOK 129.68, after deduction of the 25% discount from the volume weighted average market price on 13 February 2026. In connection with this programme, the following primary insiders have bought shares: Tom Erik Foss-Jacobsen, CEO, has bought 601 shares. Following t...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.